29 April 2023>: Database Analysis
Clinical Course of 53 Previously Vaccinated Patients Admitted to the National Hospital in Warsaw, Poland with COVID-19 Between November 2021 and March 2022
Artur Zaczyński 1AB , Michał Hampel 1AB , Paweł Piątkiewicz 2AB* , Jacek Nasiłowski 3AB , Sławomir Butkiewicz 2AB , Urszula Religioni 4DEF , Agnieszka Barańska 5CD , Maria Malm 5CD , Agnieszka Neuman-Podczaska 6DEF , Regis Vaillancourt 2ACDF , Piotr Merks 2AFGDOI: 10.12659/MSM.939841
Med Sci Monit 2023; 29:e939841
Table 3 Severity of COVID-19 vs type of vaccine.
Characteristic | N | Vaccine | P value1 | ||||
---|---|---|---|---|---|---|---|
Overall, N=53 | Astra, N=17 | Johnson, N=9 | Moderna, N=4 | Pfizer, N=23 | |||
52 | 0.915 | ||||||
Median [IQR] | 11.5 [7.8, 16.2] | 12.0 [7.0, 20.0] | 10.0 [8.0, 17.0] | 10.0 [6.0, 14.2] | 12.0 |[9.0, 14.0] | ||
Range | 1, 33 | 1, 33 | 5, 25 | 3, 18 | 4, 32 | ||
53 | 0.516 | ||||||
Yes | 10 (18.9%) | 5 (29.4%) | 2 (22.2%) | 0 (0.0%) | 3 (13.0%) | ||
No | 43 (81.1%) | 12 (70.6%) | 7 (77.8%) | 4 (100.0%) | 20 (87.0%) | ||
10 | 0.224 | ||||||
Median [IQR] | 9.0 [6.2, 10.0] | 6.0 [4.0, 10.0] | 7.5 [7.2, 7.8] | NA [NA, NA] | 10.0 [10.0, 12.5] | ||
Range | 2, 15 | 2, 13 | 7, 8 | NA, NA | 10, 15 | ||
53 | 0.244 | ||||||
Mean (SD) | 31.3 (21.5) | 33.2 (20.8) | 28.9 (12.9) | 11.2 (8.5) | 34.3 (24.9) | ||
Range | 0, 80 | 10, 80 | 10, 50 | 0, 20 | 0, 80 | ||
53 | 0.951 | ||||||
Lack | 14 (26.4%) | 5 (29.4%) | 1 (11.1%) | 1 (25.0%) | 7 (30.4%) | ||
Nasal canula | 18 (34.0%) | 7 (41.2%) | 4 (44.4%) | 2 (50.0%) | 5 (21.7%) | ||
Simple oxygen mask | 5 (9.4%) | 1 (5.9%) | 1 (11.1%) | 0 (0.0%) | 3 (13.0%) | ||
Non-rebreather mask | 15 (28.3%) | 4 (23.5%) | 3 (33.3%) | 1 (25.0%) | 7 (30.4%) | ||
High-flow oxygen therapy | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
NIV | 1 (1.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (4.3%) | ||
Respirator therapy | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
53 | 0.904 | ||||||
Lack | 7 (13.2%) | 3 (17.6%) | 0 (0.0%) | 1 (25.0%) | 3 (13.0%) | ||
Nasal canula | 11 (20.8%) | 2 (11.8%) | 2 (22.2%) | 1 (25.0%) | 6 (26.1%) | ||
Simple oxygen mask | 7 (13.2%) | 2 (11.8%) | 2 (22.2%) | 0 (0.0%) | 3 (13.0%) | ||
Non-rebreather mask | 13 (24.5%) | 3 (17.6%) | 1 (11.1%) | 2 (50.0%) | 7 (30.4%) | ||
High-flow oxygen therapy | 4 (7.5%) | 2 (11.8%) | 1 (11.1%) | 0 (0.0%) | 1 (4.3%) | ||
NIV | 5 (9.4%) | 2 (11.8%) | 1 (11.1%) | 0 (0.0%) | 2 (8.7%) | ||
Respirator therapy | 6 (11.3%) | 3 (17.6%) | 2 (22.2%) | 0 (0.0%) | 1 (4.3%) | ||
53 | 0.289 | ||||||
No change | 16 (30.2%) | 3 (17.6%) | 2 (22.2%) | 2 (50.0%) | 9 (39.1%) | ||
Worsening | 33 (62.3%) | 14 (82.4%) | 6 (66.7%) | 2 (50.0%) | 11 (47.8%) | ||
Improvement | 4 (7.5%) | 0 (0.0%) | 1 (11.1%) | 0 (0.0%) | 3 (13.0%) | ||
53 | 0.660 | ||||||
Yes | 9 (17.0%) | 4 (23.5%) | 2 (22.2%) | 0 (0.0%) | 3 (13.0%) | ||
No | 44 (83.0%) | 13 (76.5%) | 7 (77.8%) | 4 (100.0%) | 20 (87.0%) | ||
1 Kruskal-Wallis rank sum test; Fisher’s exact test; One-way ANOVA. IQR – interquartile range; ICU – Intensive Care Unit; CT – computed tomography; NIV – non-invasive ventilation. |